Beijing has mandated that Chinese companies establish internal AI ethics review committees to oversee AI activities, aiming for controllable and explainable technology. This move follows previous regulations aimed at ensuring ethical AI development.


Biotech investors are negotiating pricing deals with the White House as the Trump administration announces 100% tariffs on brand-name drugs. This comes during a busy week for mergers and acquisitions in the biotech sector.